Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06943755 · ClinicalTrials.gov registry record · Phase 2
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Phase 2 study of Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET), sponsored by Exelixis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT06943755: Recruiting Phase 2 study of Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET), sponsored by Exelixis.
NCT06943755 is a Phase 2 study of Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET) that is actively recruiting participants, run by Exelixis. The registered enrollment target is 440 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (231% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06943755, a Phase 2 study of Pancreatic Neuroendocrine Tumor (pNET) and Extra-Pancreatic Neuroendocrine Tumor (epNET), is actively recruiting participants, sponsored by Exelixis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG Everolimus
- DRUG Zanzalintinib
Study Locations (20)
California
- Exelixis Clinical Site #18 - Beverly Hills
- Exelixis Clinical Site #16 - Los Angeles
- Exelixis Clinical Site #12 - Santa Monica
- Exelixis Clinical Site #29 - Vallejo
Arizona
- Exelixis Clinical Site #36 - Phoenix
- Exelixis Clinical Site #42 - Tucson
Florida
- Exelixis Clinical Site #35 - Jacksonville
- Exelixis Clinical Site #11 - Tampa
Michigan
- Exelixis Clinical Site #47 - Detroit
- Exelixis Clinical Site #1 - Grand Rapids
Alabama
- Exelixis Clinical Site #43 - Birmingham
District of Columbia
- Exelixis Clinical Site #19 - Washington D.C.
Kentucky
- Exelixis Clinical Site #9 - Lexington
Louisiana
- Exelixis Clinical Site #23 - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
What NCT06943755 shows while recruiting
NCT06943755 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (231% higher).
The record links to 2 conditions, with Pancreatic Neuroendocrine Tumor (pNET) appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.
NCT06943755 names 20 study sites across 14 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06943755 about?
NCT06943755 is a clinical study titled "Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors". The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
What is the current status of trial NCT06943755?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 440 participants. The study started on 2025-07-21. Estimated completion is 2029-06.
What conditions does trial NCT06943755 study?
This clinical trial studies the following conditions: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET).
What interventions are being tested in trial NCT06943755?
The interventions under investigation include: Everolimus (DRUG), Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06943755?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06943755 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06943755's enrollment target sits among peer trials
440 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI